Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. - Wikidata - awgldk - TriplyDB

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.

http://www.wikidata.org/entity/Q40392451

about

Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma CD30: from basic research to cancer therapy Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.Immunotherapies for Hodgkin's lymphoma.Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.Drug development for recurrent and refractory classical Hodgkin lymphoma.Investigational antibody-drug conjugates for hematological malignancies.Targetable molecular pathways in classical Hodgkin's lymphoma.Brentuximab vedotin for the treatment of CD30+ lymphomas.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).CD30: an important new target in hematologic malignancies.Role of CD30 targeting in malignant lymphoma.Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma.CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas.Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

P2860

Q24633761-8D4FB1F7-B1AF-4B2C-AB01-CE4D3715CDC6 Q26859079-564C6ACB-2A9F-41B6-AA63-E80FA6BCD1EE Q34231085-738BA6B0-363A-4AF8-9981-EE58D52FFEF5 Q34557179-B75F2436-A47D-4EBF-B4BE-C81B15EB741E Q37006427-1528DC85-DE0C-4C42-8484-B1158C69B5FF Q37420514-598612D8-BEC5-4C3C-B774-E4F1C4700897 Q37448408-B3635E68-F758-4AC2-AF43-1C45CED7FF0D Q37818256-375FB379-BFC6-46E9-9848-B9189A6320D9 Q37825891-0DD1E10D-B700-45FC-A76A-B5311BBBB20D Q37861212-5040E3DA-4563-4EAB-BEFF-F22FEAC23C5A Q37863688-EB1BAF0E-1DCE-4592-975D-CC5F086BFC92 Q37880873-2D40AAB3-6993-45D6-9D28-445EA3D8F522 Q38191191-5DA54E5E-3E6D-46F5-B2DA-4205BA6F117E Q38205923-8B948BD1-42A3-429A-B79E-0E4379A19BCA Q38950501-491FF422-BD6F-4249-9A07-82127DC21981 Q42384513-1F78F02F-F9D9-4A02-A2EE-AFABDD5EDB28 Q47102763-C216F092-4534-47AD-A136-509EDE861332

P2860

Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.

http://www.wikidata.org/entity/Q40392451

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.

@en

type

label

Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.

@en

prefLabel

Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.

@en

P1433

Q40392451-5BF57D53-E8AA-434E-BECE-70670AB7BE72

P1476

Q40392451-B912DEE2-C8A9-4C78-B305-638C75975D9D

P2093

Q40392451-0FBDAF16-1984-484F-81B3-CD84639E1D55

Q40392451-197366E6-97CF-4523-A212-0755B49FC57F

Q40392451-24506D4A-17CD-426B-BD38-7275854DA3D0

Q40392451-6DB0572A-DB2A-42BB-9B7B-EE82945EBB43

Q40392451-90081746-37E4-4732-9756-A22F50521C48

Q40392451-9D973FDF-52EF-4172-B9D1-2373901B793E

Q40392451-C5B30E4A-0F9F-463C-979E-CF4CBCBD6D57

Q40392451-CDC15387-CFE7-439A-9283-76E20F8595B4

Q40392451-E137BC64-179D-418D-8466-D88EDA5BC181

Q40392451-E79B5143-6844-4CDC-82C0-289F93D0188A

P2860

Q40392451-0901EF25-6FED-4059-ADFF-1296D6AB9038

Q40392451-0D729A31-DB3E-4B63-B661-A9AB1DB76951

Q40392451-207C13CD-FA86-43A9-940F-0A9121DF4250

Q40392451-2C22EFB8-29CD-40E5-A83C-92C7D83D865C

Q40392451-2D97382B-030A-4551-9E67-C4F4540E925C

Q40392451-356418F1-EE96-4827-92F5-CF1317742BA8

Q40392451-363FD056-9372-4332-91F8-8A803F48FDBB

Q40392451-3D1BB3EE-6DAB-42CA-8353-120D8A6E62AE

Q40392451-431CB798-E01A-4DD5-89D4-ADABA2B1E1B3

Q40392451-43ED2632-6AD0-43BB-9D03-B10389320EFE

P2888

Q40392451-66396A33-1218-442E-B780-EEF9DAD52DB0

P304

Q40392451-50929DDD-BA4F-4514-85BD-B5C26AF0E2DD

P31

Q40392451-3318678B-2EF6-40DD-8FFE-D1403643209C

P356

Q40392451-1EC60064-5F2F-41B9-BC2E-C64E65FEE32F

P433

Q40392451-7F9435F2-602E-4C4C-A9F7-2905C8737C7F

P478

Q40392451-6FBD209E-51AA-494E-BA13-262E68364246

P577

Q40392451-FCB5B525-D45C-4939-BA3A-9F0D4615657E

P5875

Q40392451-7307DADD-040F-40B0-9BF8-5F7086B3D6A3

P6179

Q40392451-B9988ABF-F2FA-4667-907B-EF7B9244EA4C

P698

Q40392451-8E951A92-0E70-474B-83B8-BCCE0CC49923

P921

Q40392451-B9E29AF2-DCE2-42F5-83FF-C3A4C750325D

P356

P1433

P1476

Signaling via the anti-CD30 mA ...... onventional chemotherapeutics.

@en

P2093

Cerveny CG

http://www.w3.org/2001/XMLSchema#string

Francisco JA

http://www.w3.org/2001/XMLSchema#string

Hamblett KJ

http://www.w3.org/2001/XMLSchema#string

Law CL

http://www.w3.org/2001/XMLSchema#string

Lenox JS

http://www.w3.org/2001/XMLSchema#string

McCormick RS

http://www.w3.org/2001/XMLSchema#string

Petroziello JM

http://www.w3.org/2001/XMLSchema#string

Wahl AF

http://www.w3.org/2001/XMLSchema#string

Westendorf LE

http://www.w3.org/2001/XMLSchema#string

Yamane AK

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.

CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma.

Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.

AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis.

Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.

P2888

P304

1648-1655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2403884

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7695257

http://www.w3.org/2001/XMLSchema#string

P6179

1027762268

http://www.w3.org/2001/XMLSchema#string

P698

16049514

http://www.w3.org/2001/XMLSchema#string

P921